Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology

The Rise And Rise Of Artificial Intelligence

More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.

Scrip Asks, Part 4
• Source: Shutterstock

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer, Bayer’s former chief digital officer and a board member and investor for companies in the health sector. “Incumbents, investors, and founders have learned from the over-promising and under-delivering first generation of digital and are investing and implementing with much more realistic expectations of results, and importantly, reimbursements. This translates into slower but more sustainable progress.”

More from Scrip Asks

More from Scrip

Pipeline Watch: Sixteen Approvals And Seven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Bristol Gives Up On Adjuvant Melanoma For Opdualag With Failed Trial

 
• By 

The checkpoint inhibitor combo missed a recurrence-free survival endpoint in Phase III in post-surgical melanoma. The LAG-3 inhibitor-containing product continues development in lung cancer, however.